Physician profile
Ami Dalal
NPI 1598948184
$15,986.94
in general payments reported to CMS, 2019-2025
29 companies · $2,488 in 2025
The $2,488 reported for 2025 was more than what 97% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,654 · 2022: $2,892 · 2023: $6,593 · 2024: $1,360 · 2025: $2,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,270 · Consulting Fee: $3,945 · Travel and Lodging: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,269.83 |
| Consulting Fee | $3,945.00 |
| Travel and Lodging | $1,226.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $5,422.55 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $1,875.15 | 2021-2025 | Anzupgo, Adbry |
| Abbvie INC. | $1,623.04 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $964.84 | 2021-2025 | Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $954.87 | 2021-2025 | Nemluvio, Dysport |
| Amgen INC. | $747.36 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $605.56 | 2021-2023 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $540.80 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $320.97 | 2023-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $291.72 | 2021-2025 | Dupixent |
| Pfizer INC. | $282.26 | 2021-2023 | |
| Journey Medical Corporation | $281.66 | 2022-2025 | |
| Almirall LLC | $239.72 | 2021-2023 | Seysara |
| Argenx US, INC. | $227.81 | 2022-2023 | Vyvgart Hytrulo |
| Epi Health, LLC | $227.28 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $199.53 | 2021-2025 | |
| Lilly USA, LLC | $170.64 | 2021-2023 | Taltz |
| Dermavant Sciences, INC. | $165.97 | 2023 | Vtama |
| Vyne Pharmaceuticals INC. | $158.55 | 2021 | |
| Novartis Pharmaceuticals Corporation | $152.32 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $146.90 | 2021 | |
| Organon LLC | $130.02 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $68.42 | 2021-2025 | Jublia, Cabtreo, Siliq |
| Biofrontera INC. | $56.49 | 2022 | |
| Ucb, INC. | $54.62 | 2025 | Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $26.91 | 2023 | Valchlor |
| Verrica Pharmaceuticals INC. | $19.53 | 2023 | Ycanth |
| Kyowa Kirin, INC. | $15.99 | 2023 | Poteligeo |
| Solta Medical, A Division of Bausch Health US, LLC | $15.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.